期刊文献+

治疗早期帕金森病的临床证据

Evidence of Therapy of Early Parkinson’s Disease
下载PDF
导出
摘要 帕金森病是中老年人常见的中枢神经系统退行性疾病,在其早期给予合理的治疗有利于提高患者的生活质量,降低长期用药引起的运动并发症。本文介绍有关早期帕金森病治疗的临床证据,干预措施包括多巴胺受体激动剂,左旋多巴制剂,及多巴胺能神经保护剂等药物及早期步态训练等。 Patients with early Parkinson' s disease should be treated rationally in order to improve their quality of life and reduce the motor complications. The early employment of drugs which provides sustained central dopamine agonism and dopaminergic neuroprotection may reach this aim to some extent. Evidence of effective therapy in early Parkinson' s disease will be introduced including: dopamine agonists, monoamine oxidase inhibitor 13, coenzymeQ10, L-dopa and a gait training.
出处 《中国循证医学杂志》 CSCD 2005年第9期718-721,共4页 Chinese Journal of Evidence-based Medicine
关键词 早期帕金森病 临床证据 Early Parkinson' s disease Clinical evidence
  • 相关文献

参考文献29

  • 1BaroneP.Bravi D.Bermejo-ParejaF.Marconi R. Kulisevsky J. Malagu S. Weiser R. Rost N.Pergo1ide monotherapy in the treatment of early PD: a randomized,controlled study,Pergolide Monotherapy Study Group[J]. Neurology, 1999; 53(3):573-579.
  • 2Ramaker C.Van Hilten JJ. Bromocriptine versus levodopa in early Parkinson's disease(Cochrane Review).In: The Cochrane Library, Issue 3,2000.Chichester, UK:John Wiley&Sons,Ltd.
  • 3Desboeuf K.Lapeyre-Mestre M.Senard JM.Rascol O.Brefel CC.Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodova alone in previously untreated patients with Parkinson's disease[J].Movement Disorders, 12001; 6(3):511-514.
  • 4Bracco F.Battaglia A.Dupont E.Gershanik O.Marti CC.Montastruc JL. PKDS009 Study Group.The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double blind, levodopa controlled study[J]. CNS Drugs, 2004;18(11):733-746.
  • 5Ziegler N.Castro CA. Del SS.Rascol O.Efficacy of viribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study[J]. Movement Disorders, 2003; 18(4):418-425.
  • 6Korczyn AD. Thalamas C. Adler CH. Dosing with ropinirole in a clinical setting[J]. Acta Neurologica Scandinavica, 2002;106(4):200-204.
  • 7Brooks DJ.Abbott RJ.Lees AJ.Martignoni E.Philcox DV.Rascol O.Roos RA.Sagar HJ.A placebo-controlled evaluation of ropinirole,a novel D2 agonist,as sole dopaminergic therapy in Parkinson's disease[J].Clinical Neuropharmacology, 1998; 21(2):10l-107.
  • 8AdlerCH. Sethi KD.HauserRA. Davis TL. Hammerstad JP. Bertoni J. Taylor RL.Sanchez RJ.O'Brien CF. The Ropinirole Study Group. Ropinirole for the treatment of early Parkinson's diseas[J]. Neurology, 1997; 49(2):393-399.
  • 9Sethi KD.O'Brien CF. Hammerstad JP.Adler CH. Davis TL.Taylor RL. Sanchez RJ. Bertoni JM. Hauser RA.Ropinirole for the treatment of early Parkinson disease: a 12-month experience[J]. Archives of Neurology, 1998; 55(9):1211-1216.
  • 10Rascol O. Brooks DJ. Korczyn AD. De Deyn PP. Clarke CE. Lang AE.A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa[J]. NEJM, 2000; 342(20): 1 484-1 49l.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部